Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.

Heikki Joensuu, for The Finnish Breast Cancer Group, Riikka Huovinen et al.|Cancer Research|2009

Cited by 8